Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill

Diagnostic Microbiology and Infectious Disease

Volumn 73, Issue 3, 2012, Pages 287-289

  Lin, Gengrong ^a   Pankuch, Glenn A ^a   Appelbaum, Peter C ^a   Kosowska Shick, Klaudia ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Staphylococcus aureus; Telavancin; Time kill

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANALYTICAL PARAMETERS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BROTH DILUTION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS HOMINIS; TIME KILL;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COAGULASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; STAPHYLOCOCCUS; TIME FACTORS;

EID: 84862232068     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2012.04.003     Document Type: Article

References (17)

1. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition, M07-A8 2009, CLSI, Wayne, PA.
2. Clinical and Laboratory Standards Institute (CLSI) Performance standards for antimicrobial susceptibility testing twentieth informational supplement, M100-S20 2010, CLSI, Wayne, PA.
3. Cremniter J., Slassi A., Quincampoix J.-C., Sivadon-Tardy V., Bauer T., Porcher R., et al. Decreased susceptibility to teicoplanin and vancomycin in coagulase-negative staphylococci isolated from orthopedic-device-associated infections. J Clin Microbiol 2010, 48:1428-1431.
4. De Paulis A.N., Predari S.C., Chazarreta C.D., Santoianni J.E. Five-test simple scheme for species-level identification of clinically significant coagulase-negative staphylococci. J Clin Microbiol 2003, 41:1219-1224.
5. Draghi D.C., Benton B.M., Krause K.M., Thornsberry C., Pillar C., Sahm D.F. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008, 52:2383-2388.
6. Draghi D.C., Benton B.M., Krause K.M., Thornsberry C., Pillar C., Sahm D.F. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J Antimicrob Chemother 2008, 62:116-121.
7. Higgins D.L., Chang R., Debabov D.V., Leung J., Wu T., Krause K.M., et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005, 49:1127-1134.
8. Julian K., Kosowska-Shick K., Whitener C., Roos M., Labischinski H., Rubio A., et al. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother 2007, 51:3445-3448.
9. Kosowska-Shick K., Julian K.G., McGhee P.L., Appelbaum P.C., Whitener C.J. Molecular and epidemiologic characteristics of linezolid-resistant coagulase-negative staphylococci at a tertiary care hospital. Diagn Microbiol Infect Dis 2010, 68:34-39.
10. Krause K.M., Renelli M., Difuntorum S., Wu T.X., Debabov D.V., Benton B.M. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob Agents Chemother 2008, 52:2647-2652.
11. Leonard S.N., Szeto Y.G., Zolotarev M., Grigoryan I.V. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA). Int J Antimicrob Agents 2011, 37:558-561.
12. Leuthner K.D., Cheung C.M., Rybak M.J. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006, 58:338-343.
13. Lin G., Pankuch G.A., Ednie L.M., Appelbaum P.C. Antistaphylococcal activities of telavancin tested alone and in combination by time-kill assay. Antimicrob Agents Chemother 2010, 54:2201-2205.
14. Lynch A.S., Robertson G.T. Bacterial and fungal biofilm infections. Annu Rev Med 2008, 59:415-428.
15. Minto E.C., Barelli C., Martinez R., da Costa Darini A. Identification and medical importance of coagulase-negative staphylococci species. Sao Paulo Med J 1999, 117:175-178.
16. Pankuch G.A., Jacobs M.R., Appelbaum P.C. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother 1994, 38:2065-2072.
17. Trueba F., Garrabe E., Hadef R., Fabre R., Cavallo J.-D., Tsvetkova K., et al. High prevalence of teicoplanin resistance among Staphylococcus epidermidis strains in a 5-year retrospective study. J Clin Microbiol 2006, 44:1922-1923.